AngelARodriguezMD

Oncology • Austin, TX

Breast Cancer, Hematologic Oncology

Medical Oncology Director

Join to view full profile

Dr. Rodriguez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rodriguez's full profile

Already have an account?

Office
900 W 38th St
Ste 110
Austin, TX 78705
Phone+1 512-505-5500

Fax+1 512-334-2702

Education & Training

Baylor College of MedicinePost-Doctoral Fellowship, 2007 - 2009
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008
Baylor College of MedicineResidency, Internal Medicine, 2002 - 2005
Universidad Central del Caribe School of MedicineClass of 2002

Certifications & Licensure

TX State Medical License 2004 - 2026

Clinical Trials

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
Olive Oil for High Risk Breast Cancer Prevention in Women Start of enrollment: 2013 Dec 01
Completed
Phase 2, Phase 3
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel Start of enrollment: 2014 Feb 01
Completed
Phase 2
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Laura M Spring, Lauren Scarpetti, Arielle J Medford, Andrzej Niemierko, Amy Comander
NPJ Breast Cancer. 2025-01-07
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.
Tomoko Akaike, Manisha Thakuria, Ann W Silk, Daniel S Hippe, Song Youn Park
Journal of Clinical Oncology. 2024-09-10
5 citations
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.
Jacqueline A Shaw, Karen Page, Evie Wren, Elza C de Bruin, Ekaterina Kalashnikova
JCO Precision Oncology. 2024-04-01

Press Mentions

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast CancerMarch 10th, 2025
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer SymposiumNovember 25th, 2024
Catching Cancer Red-HandedDecember 1st, 2021
Join now to see all